Navigation Links
Genmab Announces Results for the First Nine Months of 2008
Date:10/29/2008

Summary: Genmab Reports Results for the Nine Month Period Ended September

30, 2008

COPENHAGEN, Denmark, October 29 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today results for the nine-month period ended September 30, 2008. During this period, Genmab reported the following results:

Genmab's revenues were DKK 667 million (USD 128 million) for the nine month period ended September 30, 2008. In the same period of 2007, Genmab recognized revenues of DKK 356 million (USD 68 million).

An operating loss of DKK 508 million (USD 97 million). This compares to an operating loss of DKK 309 million (USD 59 million) reported for the corresponding period of 2007. The larger operating loss was driven by the increased level of pre-clinical and clinical activities associated with the advancement of our product pipeline.

Net financial income for the nine month period ended September 30, 2008 reflected a net loss of DKK 18 million (USD 4 million), compared to a net income of DKK 48 million (USD 9 million) in the same period of 2007. The net financial income reflects a combination of interest income and fair market value adjustments on our portfolio of marketable securities and unrealized foreign exchange adjustments. Our net financial income was negatively impacted by the continued international financial credit crisis.

A net loss of DKK 526 million (USD 101 million) compared to a net loss of DKK 261 million (USD 50 million) for the same period in 2007. The net loss per share was DKK 11.81 (USD 2.26) for the first nine months of 2008 compared to DKK 5.97 (USD 1.14) in the first nine months of 2007.

Genmab ended the nine month period with cash and marketable securities of DKK 2.1 billion (USD 402 million), which is a decrease of DKK 1.6 billion (USD 306 million) from the end of 2007. The decrease primarily arises from the DKK 1.2 billion (USD 240 million at the date of acquisition) acquisiti
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Reaches Milestone in Ofatumumab Collaboration
2. Genmab Reaches Fifth Milestone in Ofatumumab Collaboration
3. Genmab A/S - Changes Board/Management/Auditors
4. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
5. Genmab Announces 2008 First Quarter Results
6. Passing of Genmab A/S Annual General Meeting
7. Genmab A/S - Notice to Convene Annual General Meeting
8. Genmabs 2007 Annual Report
9. Genmab Announces Year End 2007 Financial Results
10. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
11. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015  The Companion Diagnostics Deals and Alliances ... access to the partnering deals and agreements entered ... 2014. Using these reports, dealmakers will ... activities of the past year. The report series ... alliances deals announced worldwide.The initial chapters of this ...
(Date:5/27/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... and developing innovative therapies primarily in the areas ... commenced a public offering of shares of its ... common stock and overallotment purchase rights to purchase ... common stock, warrants and overallotment purchase rights are ...
(Date:5/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/l633xp/molecular ... PharmaBiotech,s new report "Molecular Diagnostics - ... offering. This report describes and ... play an important role in practice of ... biological warfare in the 21st century. This ...
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ) has ... Cancer Monoclonal Antibodies Market Outlook 2020" report ... to dominate the breast cancer monoclonal antibody segment ... Herceptin has been able to dominate this segment ... cancer cells become recalcitrant and relapsed condition could ...
Breaking Biology Technology:Companion Diagnostics Deals and Alliances of 2014 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3
... Third Wave Technologies, Inc ., a manufacturer of molecular diagnostic ... Drug Administration for approval of a new Cystic Fibrosis ... calls InPlex, is a genotyping test to determine Cystic Fibrosis ... and in diagnostic testing in newborns and children. Cystic Fibrosis ...
... and lobbyists from AT&T and BellSouth must ... the band back together and no one can stop them. , ... off the largest telecom merger in U.S. history. I always ... company. They are another step closer to proving I was right ...
... a month ago, and already Microsoft's Windows Vista , the ... bruised by critical media reports about security flaws and other shortcomings. ... the beta version. We posed several questions to Justin Jaeck, vice ... information technologies for Veridian Homes , to get their take ...
Cached Biology Technology:AT&T - BellSouth merger: Revestiture continues 2AT&T - BellSouth merger: Revestiture continues 3AT&T - BellSouth merger: Revestiture continues 4AT&T - BellSouth merger: Revestiture continues 5AT&T - BellSouth merger: Revestiture continues 6Wisconsin firms won't rush to adopt Microsoft Vista 2Wisconsin firms won't rush to adopt Microsoft Vista 3Wisconsin firms won't rush to adopt Microsoft Vista 4
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... technique that adds a new twist on the relationship ... online in The FASEB Journal ( http://www.fasebj.org ) and ... describe how they were able to coator paintviruses with ... the efficiency of some forms of gene therapy, help ...
... vertebrates, they either lay their eggs in water or on ... a team of Boston University scientists who discovered a treefrog ... frog makes a behavioral decision to lay egg masses aquatically ... a pond, where the newly-hatched tadpoles simply fall into the ...
... NEW YORK Researchers have discovered the secrets ... garden programs. A 3-year study entitled Greener Voices ... readily when given responsibility for decisionmaking and planning. ... two decades. Gardens are popping up in schools, ...
Cached Biology News:Scientists 'paint' viruses to track their fate in the body 2Reproductive plasticity revealed: Neotropical treefrog can choose to lay eggs in water or on land 2Children's gardens mushrooming 2
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
Human BMP 2 Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
... priced, full ring small animal imaging PET ... microPET R4 low retail price, it outperfoms ... count rate performance, energy resolution, timing resolution, ... small animal PET (Positron Emission Tomography) imaging ...
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
Biology Products: